Clinical trials monitoring service
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201700009C
- Awardee
-
Theradex Systems, Inc. UEI HFYTJGWFPMR7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $32,481,146
Award facts
- Opportunity
-
- Clinical Trials Monitoring Service Pre-Solicitation · N02CM7100175 · Posted Mar 10, 2021
- Clinical Trials Monitoring Service Limited / Sole Source Justification · Posted Jul 28, 2021
- Clinical Trials Monitoring Service Award Notice · Posted May 7, 2019
- Clinical Trials Monitoring Services (CTMS) Award Notice · Posted Oct 19, 2016
- Clinical Trials Monitoring Services (CTMS) Award Notice · Posted Sep 30, 2016
- Contract value 89% obligated
-
- $33,408,335.26 Current, with exercised options
- $36,506,054.26 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Princeton, NJ, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$234 | |
| Supplemental Agreement for work within scope | -$65,374 | |
| Supplemental Agreement for work within scope | -$992,399 | |
| Supplemental Agreement for work within scope | -$330,086 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $1,901,960 | |
| Exercise an Option | $6,827,856 | |
| Exercise an Option | $1,844,152 | |
| Change Order | $871,138 | |
| Exercise an Option | $4,830,352 | |
| Funding Only Action | $674,512 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $625,000 | |
| Exercise an Option | $448,168 | |
| Change Order | $4,713,736 | |
| Exercise an Option | $130,000 | |
| Exercise an Option | $872,474 | |
| Exercise an Option | $4,364,483 | |
| Exercise an Option | $665,000 | |
| Exercise an Option | $849,715 | |
| Funding Only Action | $3,250,693 | |
| Original award | $1,000,000 |
Show all 22
About this award
The National Cancer Institute awarded a definitive contract to Theradex Systems, Inc. for clinical trials monitoring service on May 1, 2017, with a ceiling value of $36.5 million and ultimate completion date of April 30, 2022.
The contract is priced on a cost-plus-fixed-fee basis with no set-aside. Place of performance is Princeton, NJ.
Service Contract Inventory reporting shows declining labor intensity across the contract's final years. FY2021 invoiced $7.3 million against 25.6 FTEs and 53,238 contractor hours, generating a blended government-paid hourly rate of $136.79. FY2022 invoiced $745 thousand against 5.5 FTEs and 11,386 contractor hours, with a derived rate of $65.40 per hour. In FY2022, three subcontractors delivered 39 percent of contractor hours.
Quick answers
Who was awarded contract HHSN261201700009C?
HHSN261201700009C was awarded to Theradex Systems, Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2017.
How much is contract HHSN261201700009C worth?
The government has obligated $32,481,146 on HHSN261201700009C. Its current value, with exercised options, is $33,408,335. Its potential value, with all options, is $36,506,054.
Was contract HHSN261201700009C competed?
The extent of competition for HHSN261201700009C was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award